文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-FAP-2286 PET显像在尿路上皮癌患者中的初步体验

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
PubMed 文献 · J Nucl Med · 2024-02-01

本研究纳入组织病理学确诊的膀胱癌患者(局部病变队列13例、转移性队列8例),行68Ga-FAP-2286 PET显像,记录阳性病灶SUVmax及大小。转移性队列和局部队列分别识别出36和18个68Ga-FAP-2286高摄取病灶,包括小于1 cm的淋巴结;5例有18F-FDG PET对比的患者中,68Ga-FAP-2286 PET病灶平均SUVmax为9.9±3.4,18F-FDG PET为4.2±1.9(n=16个病灶)。作者认为68Ga-FAP-2286显像在尿路上皮癌患者中高度敏感,可能影响临床决策。

要点

  • 68Ga-FAP-2286 PET在转移性和局部膀胱癌队列中分别识别36和18个高摄取病灶。
  • 转移性队列中14/36、局部队列中14/18个病灶为小于1 cm的淋巴结。
  • 5例对比患者中,68Ga-FAP-2286 PET病灶平均SUVmax 9.9±3.4 vs 18F-FDG PET 4.2±1.9(n=16)。

核心结论

  • 作者认为68Ga-FAP-2286显像在尿路上皮癌患者中高度敏感,可识别包括常规扫描不会引起怀疑的亚厘米淋巴结在内的多部位转移灶。
  • 作者认为这种新型显像方式可能通过细化局部淋巴结分期和发现常规影像无法检出的转移性疾病来影响肌层浸润性膀胱癌患者的临床决策。

研究设计与样本

  • 本研究为临床试验(NCT04621435)的一部分,纳入组织病理学确诊的膀胱癌患者,分为诊断时局部病变队列(n=13)和已知转移性疾病队列(n=8),行68Ga-FAP-2286 PET显像。
  • 记录68Ga-FAP-2286 PET阳性病灶的SUVmax和病灶大小;对在68Ga-FAP-2286 PET前后45天内行18F-FDG PET的患者(n=5)比较两种扫描的摄取。
  • 回顾性审阅发现影像方式不一致时,按标准诊疗对可疑病灶进行活检。

主要发现

  • 转移性队列和局部队列分别识别出36个和18个68Ga-FAP-2286高摄取病灶,分布于淋巴结、内脏转移和骨等多处解剖部位。
  • 转移性队列36个病灶中14个、局部队列18个病灶中14个为小于1 cm的淋巴结。
  • 在转移性队列中,病灶小于0.5 cm、0.5-1 cm和大于1 cm的平均SUVmax分别为5.2±2.6、9.6±3.7和13.0±4.3。
  • 在局部队列中,病灶小于0.5 cm、0.5-1 cm和大于1 cm的平均SUVmax分别为10.5±5.1、10.8±5.7和9.9±5.4。
  • 5例有18F-FDG PET对比的患者中,68Ga-FAP-2286 PET和18F-FDG PET高摄取病灶的平均SUVmax分别为9.9±3.4和4.2±1.9(n=16个病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improved imaging modalities are needed to accurately stage patients with muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma. Imaging with small-molecule ligands or inhibitors of fibroblast activation protein (FAP) is a promising modality that has demonstrated initial efficacy across a broad range of tumors. We present our experience with the novel FAP-peptide binder 68Ga-FAP-2286 in patients with MIBC. Methods: Patients with histopathologically confirmed bladder cancer who had either localized disease at diagnosis (localized cohort, n = 13) or known metastatic disease (metastatic cohort, n = 8) were imaged with 68Ga-FAP-2286 PET as part of a clinical trial (NCT04621435). The SUVmax of 68Ga-FAP-2286 PET-positive lesions and lesion size were documented. In patients who had available 18F-FDG PET performed within 45 d of 68Ga-FAP-2286 PET (n = 5), uptake on the 2 scans was compared. When there was a discrepancy between imaging modalities on retrospective review, biopsy of suggestive lesions was performed as the standard of care. Results: In the metastatic and localized cohorts, 36 and 18 68Ga-FAP-2286-avid lesions, respectively, were identified across multiple anatomic locations, including lymph nodes, visceral metastases, and bones. Fourteen of 36 lesions in the metastatic cohort and 14 of 18 lesions in the localized cohort were lymph nodes measuring less than 1 cm. Among lesions measuring less than 0.5 cm, 0.5-1 cm, and more than 1 cm, average SUVmax was 5.2 ± 2.6, 9.6 ± 3.7, and 13.0 ± 4.3, respectively, in the metastatic cohort and 10.5 ± 5.1, 10.8 ± 5.7, and 9.9 ± 5.4, respectively, in the localized cohort. Five patients had 18F-FDG PET available for comparison. The average SUVmax for lesions avid on 68Ga-FAP-2286 PET and 18F-FDG PET was 9.9 ± 3.4 versus 4.2 ± 1.9, respectively (n = 16 lesions). For 3 patients in the localized cohort, 68Ga-FAP-2286 PET informed clinical management, including identification of both false-positive findings on 18F-FDG PET and false-negative findings on conventional CT. Conclusion: 68Ga-FAP-2286 imaging is highly sensitive in patients with urothelial cancer and is effective in identifying metastatic lesions across a variety of anatomic sites, including subcentimeter lymph nodes that would not have raised suspicion on conventional scans. This novel imaging modality may inform clinical decision-making in patients with MIBC both by refining local nodal staging and by defining metastatic disease that would otherwise be undetectable on conventional imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koshkin VS, Kumar V, Kline B, et al. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024. PMID: 38212070. doi:10.2967/jnumed.123.266390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。